MA40378B1 - Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de la tétrahydroquinoléine - Google Patents
Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de la tétrahydroquinoléineInfo
- Publication number
- MA40378B1 MA40378B1 MA40378A MA40378A MA40378B1 MA 40378 B1 MA40378 B1 MA 40378B1 MA 40378 A MA40378 A MA 40378A MA 40378 A MA40378 A MA 40378A MA 40378 B1 MA40378 B1 MA 40378B1
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- synthetic intermediates
- tetrahydroquinoline derivatives
- derivatives
- cholesterol levels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne un procédé pour la préparation d'intermédiaires synthétiques qui peuvent être utilisés dans la préparation de dérivés de la tétrahydroquinoléine, lesquels dérivés ont une activité inhibitrice à l'encontre de la protéine de transfert de cholestéryle (cetp), présentent des effets d'augmentation du taux de cholestérol hdl et de diminution du taux de cholestérol ldl, et peuvent être utilisés pour le traitement et/ou la prévention de maladies telles que des maladies artériosclérotiques, une hyperlipidémie, une dyslipidémie et analogue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2014050556 | 2014-08-12 | ||
PCT/NL2015/050555 WO2016024858A1 (fr) | 2014-08-12 | 2015-07-29 | Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de tétrahydroquinoléine |
Publications (2)
Publication Number | Publication Date |
---|---|
MA40378A MA40378A (fr) | 2017-06-21 |
MA40378B1 true MA40378B1 (fr) | 2022-10-31 |
Family
ID=51429345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40378A MA40378B1 (fr) | 2014-08-12 | 2015-07-29 | Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de la tétrahydroquinoléine |
Country Status (26)
Country | Link |
---|---|
US (1) | US10112904B2 (fr) |
EP (2) | EP4083022A1 (fr) |
JP (1) | JP6670310B2 (fr) |
KR (1) | KR102572626B1 (fr) |
CN (1) | CN107108558B (fr) |
AR (1) | AR101509A1 (fr) |
AU (1) | AU2015302407B2 (fr) |
BR (1) | BR112017002873B1 (fr) |
CA (1) | CA2958040C (fr) |
CL (1) | CL2017000367A1 (fr) |
DK (1) | DK3180314T3 (fr) |
EA (1) | EA034357B1 (fr) |
ES (1) | ES2926775T3 (fr) |
HR (1) | HRP20221061T1 (fr) |
HU (1) | HUE059947T2 (fr) |
IL (1) | IL250525B (fr) |
LT (1) | LT3180314T (fr) |
MA (1) | MA40378B1 (fr) |
MX (1) | MX367908B (fr) |
PL (1) | PL3180314T3 (fr) |
PT (1) | PT3180314T (fr) |
RS (1) | RS63575B1 (fr) |
SG (1) | SG11201701077XA (fr) |
SI (1) | SI3180314T1 (fr) |
TW (1) | TWI691490B (fr) |
WO (1) | WO2016024858A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112023017999A2 (pt) | 2021-03-05 | 2023-11-14 | Newamsterdam Pharma B V | Obicetrapibe para tratamento de demências |
EP4376832A1 (fr) | 2021-07-26 | 2024-06-05 | NewAmsterdam Pharma B.V. | Traitement des hypo-répondeurs aux his |
WO2023129595A1 (fr) | 2021-12-30 | 2023-07-06 | Newamsterdam Pharma B.V. | Combinaison d'obicetrapib et d'inhibiteur de sglt2 |
WO2024009144A1 (fr) | 2022-07-05 | 2024-01-11 | Newamsterdam Pharma B.V. | Sels d'obicetrapib et leurs procédé de fabrication et leurs intermédiaires |
WO2024042061A1 (fr) | 2022-08-22 | 2024-02-29 | Newamsterdam Pharma B.V. | Polythérapie d'obicetrapib et d'ézétimibe et compositions pharmaceutiques à dose fixe |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
RU2265010C2 (ru) * | 2001-04-30 | 2005-11-27 | Пфайзер Продактс Инк. | Промежуточные соединения для ингибиторов cetp и способы их получения |
UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
TW200808731A (en) | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
CN101466679A (zh) * | 2006-03-30 | 2009-06-24 | 田边三菱制药株式会社 | 制备四氢喹啉衍生物的方法 |
-
2015
- 2015-07-29 BR BR112017002873-5A patent/BR112017002873B1/pt active IP Right Grant
- 2015-07-29 KR KR1020177006422A patent/KR102572626B1/ko active IP Right Grant
- 2015-07-29 SG SG11201701077XA patent/SG11201701077XA/en unknown
- 2015-07-29 EP EP22179712.9A patent/EP4083022A1/fr active Pending
- 2015-07-29 MX MX2017001930A patent/MX367908B/es active IP Right Grant
- 2015-07-29 EP EP15767345.0A patent/EP3180314B1/fr active Active
- 2015-07-29 AU AU2015302407A patent/AU2015302407B2/en active Active
- 2015-07-29 EA EA201790364A patent/EA034357B1/ru active IP Right Revival
- 2015-07-29 ES ES15767345T patent/ES2926775T3/es active Active
- 2015-07-29 CA CA2958040A patent/CA2958040C/fr active Active
- 2015-07-29 US US15/503,686 patent/US10112904B2/en active Active
- 2015-07-29 PL PL15767345.0T patent/PL3180314T3/pl unknown
- 2015-07-29 RS RS20220810A patent/RS63575B1/sr unknown
- 2015-07-29 LT LTEPPCT/NL2015/050555T patent/LT3180314T/lt unknown
- 2015-07-29 HR HRP20221061TT patent/HRP20221061T1/hr unknown
- 2015-07-29 DK DK15767345.0T patent/DK3180314T3/da active
- 2015-07-29 WO PCT/NL2015/050555 patent/WO2016024858A1/fr active Application Filing
- 2015-07-29 CN CN201580046606.1A patent/CN107108558B/zh active Active
- 2015-07-29 SI SI201531874T patent/SI3180314T1/sl unknown
- 2015-07-29 HU HUE15767345A patent/HUE059947T2/hu unknown
- 2015-07-29 MA MA40378A patent/MA40378B1/fr unknown
- 2015-07-29 JP JP2017528754A patent/JP6670310B2/ja active Active
- 2015-07-29 PT PT157673450T patent/PT3180314T/pt unknown
- 2015-08-10 TW TW104125888A patent/TWI691490B/zh active
- 2015-08-11 AR ARP150102597A patent/AR101509A1/es unknown
-
2017
- 2017-02-09 IL IL250525A patent/IL250525B/en active IP Right Grant
- 2017-02-10 CL CL2017000367A patent/CL2017000367A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40378B1 (fr) | Procédé de préparation d'intermédiaires synthétiques pour la préparation de dérivés de la tétrahydroquinoléine | |
MA43131B1 (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
EA201790806A1 (ru) | Иммунорегулирующие средства | |
MA53937B1 (fr) | Compositions comprenant des souches bactériennes | |
MA41013A (fr) | Compositions comprenant des souches bactériennes | |
PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
PH12017500629A1 (en) | Immuniregulatory agents | |
MX2018005096A (es) | Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular. | |
MA40290A1 (fr) | Agents immunorégulateurs | |
MA40240B1 (fr) | Composés hétéroaryle d'inhibition de la kinase | |
TN2017000134A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
MA38483A1 (fr) | Inhibiteurs de l'ido | |
PH12017500841B1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
MA39359A1 (fr) | Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés | |
MA40875B1 (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
MA45226A (fr) | Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate | |
TN2019000106A1 (en) | Novel compounds for treating parasitic disease | |
MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
MA39337A1 (fr) | Modulateurs de pyrazines de gpr6 | |
MA42455B1 (fr) | Nouveau composé hétérocyclique, procédé de préparation associé et composition pharmaceutique le comprenant | |
EA202090555A1 (ru) | Фармацевтические композиции, содержащие антитела к бета-амилоиду | |
EA201890769A1 (ru) | Производные 2,3,4,5-тетрагидропиридин-6-амина | |
MA50273A (fr) | Compositions comprenant des souches bactériennes |